Key clinical point: Results from three separate, randomized trials in epilepsy patients showed that generic lamotrigine performed identically to brand-name Lamictal.

Major finding: During chronic treatment, generic lamotrigine produced an area under the curve within 98%-103% of the brand-name, reference product Lamictal.

Data source: The prospective, randomized U.S. trials that respectively enrolled 48, 35, and 34 epilepsy patients.

Disclosures: The two EQUIGEN studies and the BEEP study had no commercial funding. Dr. Jiang had no disclosures. Dr. Privitera has received research funding from UCB, Eisai, and Neuren Pharmaceuticals and has served on the data safety and monitoring boards for trials funded by Astellas and Upsher-Smith. Dr. Ting has received research funding from Acorda and Pfizer. Dr. Gagne has received research funding from Teva and Novartis and is a consultant to Aetion. Dr. Berg has received research funding from Eisai, NeuroPace, Sunovion, Pfizer, Lundbeck, and Acorda. He also is a stockholder in and has patent rights licensed to PharmAdva and Jemsico. Dr. Spitz has been a consultant to Cyberonics.

AES: Three studies show generic lamotrigine equals Lamictal